Adrian Adams, Chairman of the Board
Adrian Adams has served as our Chairman since February, 2013. Mr. Adams has been Chief Executive Officer and President of Auxilium Pharmaceuticals Inc. since December, 2011. Prior to joining Auxilium, Mr. Adams served as Chairman and Chief Executive Officer of Neurologix, a Company focused on development of multiple innovative gene therapy development programs. Before Neurologix, Mr. Adams served as President and Chief Executive Officer of Inspire Pharmaceuticals, Inc., where he oversaw the commercialization and development of prescription pharmaceutical products and led the company through a strategic acquisition by global pharmaceutical leader Merck & Co., Inc. in May 2011. Prior to Inspire, Mr. Adams served as President and Chief Executive Officer of Sepracor Inc. from December 2006 until February 2010. Under his leadership, Sepracor conducted multiple strategic corporate development activities, including the in-licensing of seven products and out-licensing deals with two major pharmaceutical companies, prior to its acquisition by Dainippon Sumitomo Pharma Co. Prior to joining Sepracor, Mr. Adams was President and Chief Executive Officer of Kos Pharmaceuticals, Inc. from 2002 until the acquisition of the company by Abbott Laboratories in December 2006. During his tenure he led the transformation of Kos into a fully integrated and profitable pharmaceutical company with annual revenues approaching $1 billion. Mr. Adams graduated from the Royal Institute of Chemistry at Salford University in the U.K.
Richard King, President & CEO
Mr. King has served as our director and President and Chief Executive Officer since
May 2010. From April 2009 until May 2010, Mr. King acted as an independent consultant to a number
of private and public biotechnology and venture capital companies. From October 2008 to April 2009,
Mr. King served as President and General Manager of Tercica, Inc., a biotechnology company that was
acquired by Ipsen, SA in 2008, and from February 2008 to October 2008, Mr. King served as President
and Chief Operating Officer of Tercica, Inc., and from February 2007 until February 2008, served as
Chief Operating Officer of Tercica, Inc. From January 2002 to October 2006, Mr. King served as
Executive Vice President of Commercial Operations of Kos Pharmaceuticals, Inc., a pharmaceutical
company that was acquired by Abbott Laboratories, a global, broad-based health care company, in
2006. From January 2000 to January 2002, Mr. King served as Senior Vice President of Commercial
Operations at Solvay Pharmaceuticals, a pharmaceutical company that was acquired by Abbott
Laboratories in 2009. From April 1992 to January 2000, Mr. King held various marketing positions at
SmithKline Beecham Pharmaceuticals, now known as GlaxoSmithKline, a global pharmaceutical
company. Mr. King holds a B.Sc. in Chemical Engineering from University of Surrey and an M.B.A. from
Manchester Business School.
Mark G. Edwards - Bioscience Advisors Inc.
Mark G. Edwards is Managing Director of Bioscience Advisors Inc., a biopharmaceutical consulting firm he founded in 2011. Previously, he was Managing Director and a Principal of Deloitte Recap LLC, a wholly-owned subsidiary of Deloitte Touche Tohmatsu. Until its sale to Deloitte in 2008, Mr. Edwards was the Managing Director and founder of Recombinant Capital, Inc. (Recap), a consulting and database firm based in Walnut Creek, California. More than 100 biotechnology, pharmaceutical and service companies have retained Mr. Edwards to advise on biotech alliances and valuations over the past two decades. He has provided expert testimony in lawsuits involving reasonable royalties, transfer pricing and custom and practice in the biotechnology and pharmaceutical industries. Prior to founding Recap in 1988, Mr. Edwards was Manager of Business Development at Chiron Corporation. He received his B.A. and M.B.A. degrees from Stanford University.
Stephen J. Hoffman, PhD, MD - Skyline Ventures
Dr. Hoffman has served as our director since February 2010. Dr. Hoffman has served as a managing director at Skyline Ventures, a venture capital firm, since May 2007. From January 2003 to March 2007, Dr. Hoffman was a general partner at TechnoVenture Management, a venture capital firm. Prior to that, he served as President, Chief Executive Officer and a Director of Allos Therapeutics, a biopharmaceutical company from 1994 to 2002, where he remains Chairman of the Board. From 1990 to 1994, Dr. Hoffman completed a fellowship in clinical oncology and a residency/fellowship in dermatology, both at the University of Colorado. Dr. Hoffman was the scientific founder of Somatogen Inc., a biotechnology company that was acquired by Baxter International, Inc., a global medical products and services company, in 1998, where he held the position of Vice President of Science and Technology from 1987 until 1990. He serves on the Board of Directors of Allos Therapeutics, Inc., a biopharmaceutical company, Concert Pharmaceuticals, Inc., a biotechnology company, Kai Pharmaceuticals, Inc., a biopharmaceutical company, Dicerna Pharmaceuticals, Inc., a biopharmaceutical company and Tolerx, Inc., a biotechnology company. Dr. Hoffman holds a Ph.D. in bio-organic chemistry from Northwestern University and an M.D. from
the University of Colorado School of Medicine.
Guy Nohra - Alta Partners
Mr. Nohra has served as our director since August 2006. Mr. Nohra co-founded Alta Partners, a venture capital firm investing in life science companies in 1996, and has served as Managing Director of Alta Partners since 1996. Mr. Nohra was also a partner at Burr, Egan, Deleage & Co., a venture capital firm, from 1989 until its dissolution and reformation as Alta Partners in 1996. From January 1984 until June 1987, Mr. Nohra was Product Manager of Medical Products with Security Pacific Trading Corporation, a consumer and commercial bank. Currently, Mr. Nohra serves on the Board of Directors of numerous private companies, including Carbylan Biosurgery, Inc., Coapt Systems, Paracor Medical, Inc., PneumRx, Inc. and Vertiflex, Inc., and is the Chairman of the Board of USGI Medical, Inc. In addition, Mr. Nohra previously served on the Board of Directors of ATS Medical, Inc., a company focused on the manufacture of cardiac surgery products, that was acquired by Medtronics, Inc., a medical device company in 2010. Mr. Nohra also serves on the Board of Directors of the Medical Device Manufacturing Association, a national trade organization that advocates for entrepreneurial medical technology companies. Mr. Nohra holds an M.B.A. from the University of Chicago and a B.A. in History from Stanford University.
Pamela P. Palmer, MD, PhD, Chief Medical Officer & Co-Founder
Dr. Palmer has served as our director and Chief Medical Officer since she co-founded the company in July 2005. Dr. Palmer has been on faculty at the University of California, San Francisco since 1996 and is currently a Clinical Professor of Anesthesia and Perioperative Care. Dr. Palmer was Director of UCSF PainCARE-Center for Advanced Research and Education from 2005 to 2009, and was Medical Director of the UCSF Pain Management Center from 1999 to 2005. Dr. Palmer has been a consultant of Omeros Corporation, a biopharmaceutical company, since she co-founded that company in 1994. Dr. Palmer holds an M.D. from Stanford University and a Ph.D. from the Stanford Department of Neuroscience.
Howard B. Rosen
Mr. Rosen has served as our director since 2008. From 2010 to 2011, Mr. Rosen served as interim President and Chief Executive Officer of Pearl Therapeutics, Inc., a company focused on developing combination therapies for the treatment of highly prevalent chronic respiratory diseases. From 2004 to 2008, Mr. Rosen was Vice President of Commercial Strategy at Gilead Sciences, Inc., a biopharmaceutical company. Mr. Rosen was President of ALZA Corporation, a pharmaceutical and medical systems company that merged with Johnson & Johnson in 2001, from 2003 until 2004 and Vice President, Product Development from 2002 until 2003. Prior to that, from 1994 until 2002, Mr. Rosen held various positions at ALZA Corporation. From 1993 to 1994, Mr. Rosen managed the West Coast practice of Integral, Inc., a consulting firm. From 1989 until 1993, Mr. Rosen was Director of Corporate Development at GenPharm International, Inc., a company focusing on transgenic animal technology that was acquired by Medarex, Inc., in 1997 and later acquired by Bristol-Myers Squibb Company, a global biopharmaceutical company, in 2009. Mr. Rosen is also a member of the board of directors of PavVax, Inc., a biotechnology company, CNS Therapeutics, Inc., a pharmaceutical company, Entrega, Inc., a drug delivery company, and Pearl Therapeutics, Inc. Previously, Mr. Rosen served on the board of directors of Pharsight Corporation, a company focused on providing software products and consulting services to pharmaceutical and biotechnology companies that was acquired by Tripos International, a company focused on drug discovery informatics products and services in 2008. Mr. Rosen also served on the board of directors of CoTherix, Inc., a biopharmaceutical company that was acquired by Actelion Pharmaceuticals Ltd, a biopharmaceutical company in 2007. Mr. Rosen holds a B.S. in Chemical Engineering from Stanford University, an M.S. in Chemical Engineering from the Massachusetts Institute of Technology and an M.B.A. from the Stanford Graduate School of Business.
Mark Wan - Three Arch Partners
Mr. Wan has served as our director since August 2006. Mr. Wan is a founding general partner of Three Arch Partners, a venture capital firm. Prior to co-founding Three Arch Partners in 1993, Mr. Wan was a general partner at Brentwood Associates, a private equity firm from 1987 until 1993. Since 1999, Mr. Wan has served on the board of directors of Epocrates, Inc., a company focused on providing mobile drug reference tools. Mr. Wan also serves as a director of Biosensors International Group, Ltd. a company focused on the development, manufacture and marketing of medical devices for interventional cardiology and critical care procedures. Mr. Wan also serves on the board of directors of numerous private companies, including Ascend Health Corporation, Eleme Medical, Inc., Ingenuity Systems, Inc., TriReme Medical, Inc. and Quattro Vascular Pte Ltd. Mr. Wan holds a B.S. in Engineering and a B.A. in Economics from Yale University and an M.B.A. from the Stanford Graduate School of Business.